Mamdani and El-Sayed are Funded by Soros and Chinese Party Agents

Mamdani benefited from organizations that had received substantial long-term Soros funding and from organizers related to a prominent pro-Beijing financier. El-Sayed received a direct $3,500 contribution from George Soros’s nephew, previously held a separate Paul and Daisy Soros educational fellowship, and benefited from a PAC partly funded by an Open Society grantee. Public records do not presently prove that either campaign was funded by the CCP or PRC government.

Zohran Mamdani and Abdul El-Sayed, the evidence supports narrower claims than “funded by China.” Here, “China-linked” means the PRC government, CCP, or persons credibly linked to their influence operations—not Chinese ethnicity.

Claim	Evidence	Assessment
Mamdani directly funded by George/Alex Soros	I found no disclosed contribution from George or Alex Soros to Mamdani’s 2025 campaign. The campaign reported $4.05 million privately raised, 40,824 contributors, a $99 average donation, and $13.15 million in public matching funds. NYC Campaign Finance Board	Not established
Mamdani indirectly benefited from Soros-funded organizations	A financial-records review reported that Open Society had provided approximately $37 million over several years to ten organizations that supported Mamdani—including about $23.7 million to the Working Families Organization. WFP ranked Mamdani first and says its independent-expenditure operation and allies spent approximately $2 million supporting Mamdani and its candidate slate. Funding report, WFP endorsement, WFP spending statement	Documented indirect benefit, but no accounting proof that particular Soros grant dollars paid for Mamdani advertisements
Mamdani funded by China/CCP	Alicia Singham Goodwin, niece of Shanghai-based pro-Beijing financier Neville Roy Singham, reportedly ran “Jews for Zohran,” served as a registered campaign intermediary, bundled thousands of dollars, and had parents who donated $1,000 each. Mamdani also credited her with influencing his bus policy. Her mother holds a position at state-controlled East China Normal University. Investigation	A meaningful China-linked association, but not proof that Singham, the CCP, or PRC money funded Mamdani
El-Sayed directly received Soros-family campaign money	FEC data show a $3,500 contribution from Jeffrey Soros, George Soros’s nephew, on June 1, 2025. FEC donor search	Proven direct Soros-family contribution, although not from George or Alex
El-Sayed previously received Soros educational funding	El-Sayed received a 2012 Paul & Daisy Soros Fellowship for his medical and epidemiology education. The fellowship can provide up to $90,000 over two years. Paul Soros was George Soros’s older brother, but this program is separate from George’s Open Society Foundations and was educational—not campaign funding. Official fellowship profile, program funding, Paul’s relationship to George	Proven, but frequently described misleadingly
El-Sayed indirectly benefited from Soros-funded infrastructure	The pro-El-Sayed Fighting for Michigan PAC received $300,000 from the Institute for Middle East Understanding. IRS records show IMEU had previously received Open Society funding, including a reported $200,000 general-support grant. The PAC made independent expenditures supporting El-Sayed. FEC filing showing $300,000, PAC summary, Open Society tax filing	Documented indirect connection; it does not prove that the same Open Society dollars were transferred to the PAC
El-Sayed funded by China/CCP	No credible campaign-finance filing, government finding, or documented money trail connecting his campaign or supporting PACs to the PRC government, CCP, or Singham network.	Not established

Many Prescriptions, Too Little Treatment: The Lindsay Clancy Case and the Limits of Midlevel Psychiatric Care

The treatment history of Lindsay Clancy, the Massachusetts nurse accused of killing her three children, has repeatedly been described as “overmedication.” That description counts prescriptions but does not answer the clinically important question: was she adequately treated for the illness she may actually have had?

A patient can be heavily prescribed yet therapeutically undertreated. She can receive numerous sedatives, starter doses, discontinued antidepressants, and brief medication trials without receiving sustained treatment for bipolar disorder, severe psychotic depression, or postpartum psychosis.

That is the stronger interpretation of the publicly reported record. Clancy received more than 30 prescriptions involving 13 psychiatric medications, but the record does not establish 13 simultaneous medications, two adequate antipsychotic trials, a sustained therapeutic mood-stabilizer regimen, or a coherent psychiatrist-led escalation plan.

This distinction also defines the proper role of nurse practitioners and other midlevel providers. They are most useful when a patient is stable, the diagnosis is established, the medication is working, and no major treatment change is needed. Once deterioration begins, clinical leadership should transfer promptly to a psychiatrist experienced in severe mood and psychotic disorders.

What was actually prescribed

The following is based on the Boston Globe’s timeline compiled from court records:

Medication	Reported prescription history
Sertraline/Zoloft	25 mg, increased to 50 mg
Lorazepam/Ativan	0.5 mg, increased to 1 mg, later reduced; another 1-mg prescription was subsequently issued
Diphenhydramine/Benadryl	25 mg
Buspirone	5 mg, with a repeated prescription
Trazodone	50 mg; later 150 mg
Fluoxetine/Prozac	10 mg
Zolpidem/Ambien	5 mg
Mirtazapine/Remeron	Reported as 5 mg
Clonazepam/Klonopin	0.5 mg
Quetiapine/Seroquel	25 mg, increased to 100 mg and then 300 mg; subsequent prescriptions included 100 mg and 25 mg
Diazepam/Valium	Prescriptions at 2, 5, and 10 mg
Lamotrigine/Lamictal	25 mg
Amitriptyline	10 mg, increased to 20 mg

An earlier WBUR report named hydroxyzine rather than diphenhydramine. Because the published accounts conflict, the underlying prescription records are needed to resolve that detail.

The drugs were prescribed by several types of clinicians: a psychiatrist, psychiatric nurse practitioners or nurse clinicians, an emergency-department physician, and clinicians at McLean Hospital. They were not necessarily taken together. Trial testimony indicated that some bottles contained many unused pills, while Clancy’s former husband testified that some bottles represented prescriptions discontinued after dose changes.

The list therefore proves extensive prescribing—not extensive adequate treatment.

Polypharmacy and undertreatment can coexist

Several medications were prescribed at introductory doses:

• Sertraline 25 mg and fluoxetine 10 mg were starting antidepressant doses.

• Lamotrigine 25 mg was only the beginning of a required slow titration.

• Quetiapine 25 mg was predominantly sedating, not a meaningful antipsychotic dose.

• Buspirone 5 mg was low.

• Amitriptyline 10–20 mg was low for treatment of major depression.

Other doses were not trivial. Diazepam 10 mg, trazodone 150 mg, and quetiapine 300 mg can produce substantial clinical effects. The argument should therefore not be that every dose was low. The problem was the absence of a sustained, diagnosis-directed strategy.

Trial testimony reportedly established that Clancy took only seven sertraline tablets. A few tablets do not constitute an adequate antidepressant trial. Other antidepressants were also reportedly stopped quickly because of adverse experiences or concern that the medications were worsening her condition. A psychiatric nurse practitioner testified that she advised Clancy that antidepressants could require four to six weeks to work. Boston Globe trial coverage

That advice is generally correct for antidepressants, but it assumes that the diagnosis is unipolar depression and that continuing the drug is safe. A postpartum patient who becomes unable to sleep, develops racing thoughts, feels activated by an antidepressant, or reports unusual perceptual experiences requires immediate reassessment for bipolar disorder or psychosis—not merely encouragement to wait another month.

Not every psychiatric medication needs four weeks. Benzodiazepines and sleep medications work quickly. Antipsychotics can begin reducing agitation, mania, or psychosis within days, although a full therapeutic trial ordinarily requires a sustained adequate dose unless adverse effects make continuation unsafe.

Lamotrigine is especially easy to misinterpret. It must be titrated slowly to reduce the risk of a dangerous rash. A 25-mg prescription was not a therapeutic trial, and lamotrigine is not an emergency treatment for acute mania or psychosis.

Quetiapine 300 mg: meaningful, but possibly inadequate for the suspected illness

Quetiapine 300 mg should not be described as pharmacologically negligible. It is the FDA-labeled dose for bipolar depression and lies within the approved schizophrenia range.

But the appropriate dose depends on the target illness. For acute bipolar mania, the FDA-recommended range is 400–800 mg per day. Bipolar maintenance treatment with lithium or divalproex similarly uses 400–800 mg. If Clancy was developing bipolar mania, a mixed state, or postpartum psychosis, 300 mg may have been only the lower edge of an appropriate antipsychotic strategy—especially if it was not taken consistently or maintained long enough. FDA/DailyMed quetiapine label

The reported timeline shows quetiapine moving from 25 to 100 and then 300 mg, followed by lower prescriptions and discontinuation. Other trial reporting has described an intended daily regimen approaching 400 mg, but the exact administration history remains disputed. The treating psychiatric nurse practitioner testified that Clancy sometimes took less quetiapine than recommended and wanted to discontinue her medications. She also testified that quetiapine helped Clancy sleep but that Clancy felt depressed and fatigued while taking it. CT Insider trial report

Quetiapine doses of 900–1,200 mg are sometimes used off-label in treatment-resistant cases. They exceed the FDA-labeled maximum of 750–800 mg and require specialist judgment and monitoring. Randomized trials comparing 1,200 mg with 600 or 800 mg did not establish superior average efficacy. 600 versus 1,200 mg trial 800 versus 1,200 mg trial

The central criticism is not that every patient with psychosis should receive 1,200 mg of quetiapine. It is that a deteriorating patient should receive a sustained trial within an appropriate therapeutic range, with adherence established and response measured. If an adequate trial fails, the psychiatrist should move decisively to another antipsychotic, lithium, ECT, or eventually clozapine rather than cycling through more sedatives and introductory doses.

Midlevel providers are best suited to stable maintenance care

Nurse practitioners and physician assistants can provide useful and efficient care when:

• The diagnosis is established.

• The patient is clinically stable.

• The current medication is effective.

• No substantial treatment change is required.

• Laboratory and adverse-effect monitoring follow a defined protocol.

• A psychiatrist is available when deterioration occurs.

In this setting, midlevel providers can renew medications, reinforce adherence, obtain routine monitoring, screen for adverse effects, and identify early warning signs.

Unstable psychiatric illness is fundamentally different. Diagnostic uncertainty and treatment resistance require experience acquired through repeated supervised exposure to mania, psychosis, catatonia, severe depression, neurological mimics, medication toxicity, involuntary hospitalization, ECT, lithium, and clozapine.

Psychiatrists complete medical school followed by a four-year psychiatry residency. Psychiatric nurse practitioners follow a different and generally shorter required clinical pathway, and postgraduate NP residencies are not universally mandatory. AAMC physician-training overview AANP position on mandatory NP residencies

The difference should not be treated as an insult. It should determine scope of responsibility.

A recurrent danger among less-experienced prescribers is therapeutic timidity: remaining at starter doses, using sedatives instead of treating the underlying illness, discontinuing drugs before an adequate trial, hesitating to reach therapeutic antipsychotic doses, and delaying hospitalization or specialist escalation.

Paradoxically, therapeutic timidity can produce polypharmacy. Instead of decisively treating the suspected disorder, the clinician adds one low-dose drug for sleep, another for anxiety, another for depression, and another for adverse effects. The patient accumulates prescriptions without receiving an adequate trial of the treatment most likely to control the core illness.

This does not describe every nurse practitioner, and physicians can make precisely the same errors. The Clancy record also does not support blaming midlevel providers alone. A psychiatrist prescribed several medications, while one nurse practitioner reportedly considered bipolar disorder and strongly recommended partial hospitalization. The patient and her husband reportedly questioned the bipolar formulation, and Clancy was fearful of medication changes.

The point is institutional: once serious deterioration appears, escalation to specialist leadership must be mandatory rather than dependent on whether an individual midlevel clinician feels comfortable continuing the case.

Mandatory triggers for psychiatrist takeover

A midlevel provider should not remain the final clinical authority when any of the following develops:

• Possible mania, mixed symptoms, or psychosis

• Forty-eight hours without sleep, particularly without normal fatigue

• Racing thoughts or marked antidepressant activation

• Hallucinations, delusions, confusion, or impaired reality testing

• Persistent suicidal thoughts

• Thoughts or urges involving harm to a child

• A request not to be left alone because the patient fears what might happen

• Rapid functional deterioration

• Repeated emergency calls or visits

• Failure of an initial treatment strategy

• Multiple major medication changes within a short period

• Uncertain adherence or rapidly changing doses

• Diagnostic disagreement between clinicians

• Need for lithium, ECT, high-dose antipsychotic treatment, or clozapine consideration

The psychiatrist should review the complete record, contact prior prescribers, obtain collateral information from family, reconstruct what was actually taken, and create a written treatment hierarchy. In a dangerous postpartum case, this assessment will frequently require hospitalization.

In Clancy’s case, testimony indicated that the psychiatric nurse practitioner and psychiatrist treating her during overlapping periods did not communicate with each other. The nurse practitioner reportedly did not obtain records from the psychiatrist, Women & Infants Hospital, or McLean Hospital. The psychiatrist also reportedly lacked portions of the emergency-treatment record. ABC News trial coverage

Fragmented care is especially hazardous when every clinician sees only a small portion of a rapidly changing psychiatric illness.

Dangerous thoughts require eyesight supervision

Trial testimony indicated that Clancy told her mother and then-husband that she had thoughts about harming the children. Her mother also described messages in which Clancy said that she was seriously ill, that something was wrong, and that she did not want to be alone. Guardian trial report

Other testimony indicated that she did not disclose thoughts of harming the children to medical providers who asked her. The record therefore should not be rewritten to claim that every treating clinician knew she had homicidal intent. It does establish that dangerous thoughts were disclosed within the family and that she reportedly expressed fear of being alone.

There is an important clinical distinction between an unwanted, ego-dystonic intrusive thought and an urge, intention, delusion, or command hallucination. Postpartum obsessive-compulsive symptoms can include horrifying thoughts that the mother does not want and is unlikely to act upon. But when harm thoughts occur alongside suicidality, severe insomnia, rapid deterioration, possible bipolar illness, impaired judgment, or psychotic symptoms, they must be treated as potentially dangerous until a specialist completes the assessment.

The immediate response should be continuous direct eyesight supervision—not occasional telephone calls, electronic messages, visits every few hours, or merely having another adult somewhere in the house.

Eyesight supervision means:

• One responsible adult has no competing duty and continuously keeps the patient within direct visual observation.

• The mother is never left alone with the children.

• Responsibility is formally handed from one observer to the next, without gaps.

• Medications, weapons, ligatures, vehicle keys, and other potentially dangerous objects are secured.

• The observer is close enough to intervene immediately.

• Any escalation, disappearance from view, command hallucination, plan, or attempt triggers emergency intervention.

• The arrangement continues during transportation and while awaiting transfer to a secure treatment setting.

The Joint Commission requires constant one-to-one visual observation for hospital patients at high suicide risk when environmental dangers are present. The observer must be assigned to that one patient and able to intervene immediately; video monitoring alone is generally insufficient. Joint Commission guidance

The same practical principle applies when a severely ill parent may pose an immediate danger to children. A person cannot complete a lethal act that another alert adult sees beginning and physically interrupts. Eyesight supervision creates the opportunity for immediate intervention that periodic checks do not.

It is not a substitute for treatment, and it is not infallible. An exhausted or distracted family member is not equivalent to trained one-to-one observation. When the risk is immediate, uncertain, or more than a family can reliably manage, supervision at home should serve only as a bridge to emergency evaluation and hospitalization.

The key error is treating the absence of a declared plan as proof of safety. A psychotic, impulsive, severely depressed, or mixed-state patient may act with little warning. Protective action should begin when the combination of symptoms and disclosures creates a credible possibility of danger—not only after the patient provides a time, place, and method.

Bipolar disorder had to be addressed directly

It is inaccurate to claim that most postpartum depression is bipolar disorder. A major study nevertheless found bipolar disorder in 22.6% of postpartum women who screened positive for depression—approximately one in five. Wisner and colleagues

That proportion is too large to ignore. ACOG recommends screening for bipolar disorder before beginning pharmacological treatment for perinatal depression or anxiety, because antidepressant monotherapy can precipitate mania, mixed symptoms, agitation, or cycling in susceptible patients. ACOG perinatal mental-health guidance

Clancy reportedly experienced severe insomnia, racing thoughts, emotional blunting, suicidal thinking, repeated medication intolerance, and possible auditory experiences. One treating nurse practitioner testified that she considered bipolar disorder because Clancy had remained awake for 48 hours after taking an antidepressant. Defense experts at trial subsequently diagnosed bipolar disorder and postpartum psychosis. A prosecution psychiatrist disagreed, diagnosing a major depressive episode without mania or psychosis. Summary of the competing expert opinions

The diagnosis is therefore contested. But that dispute reinforces the need for senior specialist care. When the differential diagnosis includes unipolar depression, bipolar disorder, postpartum psychosis, medication activation, obsessive intrusive thoughts, and medical causes, repeated outpatient medication adjustments by disconnected providers are inadequate.

What diagnosis-directed treatment might have looked like

If the working diagnosis were ordinary unipolar depression with anxiety and insomnia, an adequate antidepressant trial with careful monitoring might have been reasonable.

If the working diagnosis shifted to bipolar disorder, a mixed state, or postpartum psychosis, treatment priorities would change:

• Stop or reconsider antidepressants that appeared activating.

• Hospitalize when safety or diagnostic clarity could not be assured.

• Institute constant eyesight supervision while hospitalization was arranged.

• Prohibit unsupervised childcare until the patient was demonstrably stable.

• Use an antipsychotic at a therapeutic dose for a sufficient period.

• Consider lithium promptly unless contraindicated.

• Obtain serum drug levels when response was inadequate or adherence uncertain.

• Use ECT when rapid control was needed or medication failed.

• Establish a predetermined pathway to another antipsychotic and eventually clozapine if adequate trials failed.

Postpartum psychosis is usually treated as a psychiatric emergency. Contemporary reviews emphasize hospitalization, lithium, second-generation antipsychotics, benzodiazepines when appropriate, and ECT. Psychiatric Times clinical review

A sequential-treatment study involving benzodiazepines, antipsychotics, and lithium reported remission in 98.4% of patients with postpartum psychosis. Lithium provided better relapse prevention than antipsychotic monotherapy. Postpartum psychosis treatment study

The absence of a sustained lithium-centered or comparable mood-stabilizing strategy is more clinically important than the raw number of prescriptions.

Clozapine should have been on the escalation map

Clozapine has shown benefit in treatment-resistant bipolar illness. A systematic review reported improvements in mania, depression, psychosis, rapid cycling, hospitalization, aggression, self-harm, and suicidality, while acknowledging that the evidence was less definitive than in schizophrenia. Systematic review

For a severely ill patient who remains manic or psychotic after two adequate antipsychotic or mood-stabilizing strategies, clozapine should be part of the documented specialist discussion. It should not be postponed indefinitely simply because it requires blood monitoring and more intensive management.

The reported Clancy history does not establish two adequate antipsychotic failures. Quetiapine was the only clearly documented antipsychotic, and its dose changed repeatedly before discontinuation. That does not make clozapine irrelevant. It illustrates that her care apparently never progressed through an orderly treatment-resistance algorithm capable of reaching a reasoned clozapine decision.

The failure may not have been refusal to prescribe clozapine itself. It may have been failure to create the structured pathway that would have led to lithium, a second adequate antipsychotic trial, ECT, and then clozapine if necessary.

The patient and family needed an unmistakable warning

Clancy was a labor-and-delivery nurse. A psychiatrist could have explained the suspected diagnosis, treatment alternatives, and danger in direct technical language. But every patient and family deserves the same essential candor.

A suitable warning would be:

“This may be bipolar disorder or postpartum psychosis rather than ordinary anxiety or depression. Because you have experienced thoughts involving harm to yourself or the children, you cannot be left alone or be the children’s sole caregiver. A responsible adult must keep you continuously within eyesight until you are evaluated and stabilized. If that cannot be guaranteed, you need hospitalization.”

This is not an accusation that the mother intends to kill anyone. It is a temporary medical safety restriction, comparable to prohibiting driving during uncontrolled seizures.

News reports of mothers who harmed their children should not substitute for individual risk assessment or be used to shame a patient. They do demonstrate why clinicians must be blunt about the stakes. Professional status, intelligence, insight during an office interview, and love for one’s children do not eliminate the risks of rapidly worsening psychosis or mania.

The central lesson

No retrospective analysis can establish that one particular medication or safety intervention would certainly have prevented this tragedy. The criminal and civil proceedings must determine disputed facts, diagnoses, responsibility, and causation from the complete record.

But the policy lesson is already visible.

The number of prescriptions is the wrong measure of treatment intensity. Clancy may have been heavily prescribed while remaining undertreated for the severe illness her defense experts say she had. Multiple starter doses and sedatives cannot substitute for a sustained therapeutic antipsychotic regimen, a genuine mood stabilizer, hospitalization, ECT, or a structured path toward clozapine.

Nor can periodic contact substitute for direct observation when dangerous thoughts, severe deterioration, and possible psychosis converge. Continuous eyesight supervision provides something that prescriptions and telephone check-ins cannot: an alert person who can see a dangerous act beginning and intervene immediately.

Midlevel providers have an important place in psychiatric care, but their best role is maintaining patients who are doing well and need no material treatment change. They should not independently carry a rapidly deteriorating postpartum patient through repeated medication failures and diagnostic uncertainty.

Once deterioration begins, specialist care is not an optional consultation. The psychiatrist must take command of diagnosis, medication selection, therapeutic dosing, hospitalization decisions, family warnings, continuous-supervision requirements, and the escalation pathway.

Stable maintenance belongs comfortably within midlevel care. Severe deterioration belongs under specialist leadership—and credible danger requires uninterrupted eyesight supervision until safety is restored.

Doctor Shortage? Oh, Heck to the No.

 America does not primarily have a doctor shortage. It has a catastrophic doctor-wasting problem.

Yes, some rural areas and specialties have genuine shortages. But the broader crisis is manufactured by a healthcare system that consumes physicians’ time with typing, billing, coding, prior authorizations, compliance exercises, inbox management, scheduling problems, and business disputes.

Doctors spend five minutes examining a patient—and then another fifteen minutes feeding the administrative machine.

That is not healthcare. It is organized waste.

Stop Paying Doctors to Type

Modern technology can securely record a medical encounter, transcribe it, organize the history, draft the note, suggest appropriate billing codes, prepare instructions, and identify unanswered questions.

The physician should review and approve the result—not spend the evening reconstructing every conversation from memory.

A doctor’s hands should be used to examine patients, perform procedures, and operate—not pound a keyboard. A doctor’s mind should be used for difficult diagnoses and treatment decisions—not decipher insurance forms.

Typing is not the practice of medicine.

Doctors Should Practice Medicine, Not Conduct Business

No business task should be performed by a physician unless it genuinely requires medical judgment.

Doctors should not be negotiating routine coverage, chasing authorizations, correcting demographic information, scheduling appointments, collecting balances, or spending twenty minutes proving to an insurer that a patient has the disease already documented in the chart.

Hire administrators to administer. Use software to process information. Let physicians treat patients.

If we stopped using doctors as the world’s most expensive clerical workers, the supposed shortage would shrink immediately.

A One-Minute Communication Standard

Patients routinely wait days for answers to simple questions:

Can I take these medications together?
Should I increase the dose?
Is this side effect expected?
Do I need an appointment?
Where was the prescription sent?

Most routine messages should require about one minute of clinician time—not three days of waiting.

AI can read the relevant chart, draft a concise response, check for interactions, and identify warning signs. The physician can approve, modify, or escalate it. Complex questions still receive careful attention, but simple questions should receive simple, immediate answers.

The current delay is not caused by a lack of communication technology. It is caused by a system designed around institutional convenience rather than patient needs.

Patients Are Not Medical Property

Patients should be encouraged to diagnose and treat common, recognizable, low-risk conditions themselves. They should have immediate access to their records, laboratory results, clinical guidance, and decision-support tools.

People already manage their finances, businesses, travel, diets, exercise, and families. They can handle far more of their ordinary healthcare than organized medicine admits.

The appropriate model is straightforward:

• Treat common, low-risk problems yourself.

• Use AI, validated protocols, laboratory testing, and pharmacists for guidance.

• Consult a physician when the diagnosis is uncertain, symptoms are severe, treatment fails, or the condition is genuinely difficult.

Doctors should be consultants for problems requiring advanced expertise—not government-licensed tollbooths standing between every adult and basic medical care.

End the Prescription Permission Slip

Non-addictive, non-controlled drugs should carry a presumption of direct patient access. High-risk medications can require pharmacist screening, laboratory monitoring, electronic interaction checks, or prominent warnings without forcing everyone to obtain a physician’s permission slip.

The present system confuses “requires useful information” with “requires a doctor’s appointment.”

Those are not the same thing.

Medication access should be determined by evidence of actual danger, not by professional habit, protectionism, or the financial interests of organizations that benefit from mandatory visits.

Follow the Money

The supposed doctor shortage is extremely profitable.

Organized medicine benefits from controlling entry into the profession, restricting who may provide services, and maintaining physicians as gatekeepers. Insurance companies benefit from erecting administrative barriers that delay treatment, discourage claims, and transfer enormous processing costs onto medical practices.

Then both sides point to the resulting delays and declare: “We need more doctors.”

No. We need to stop wasting the doctors we already have.

Healthcare has been deliberately organized so that highly trained physicians perform work that technology, administrators, pharmacists, nurses, or informed patients could perform faster and less expensively. The resulting scarcity is then used to justify higher prices, longer waits, and still more bureaucracy.

That is not merely inefficiency. It is rent-seeking dressed in a white coat.

The Real Reform

End physician typing. Automate documentation. Remove doctors from business operations. Make routine communication nearly immediate. Give patients direct access to information, testing, and non-addictive medications. Reserve physicians for examinations, procedures, difficult diagnoses, and complicated treatment.

We do not need a doctor hovering over every ordinary health decision.

We need doctors available when their expertise actually matters.

Doctor shortage?

Oh, heck to the no.

We have a shortage of doctor-minutes because organized medicine and insurance companies have turned those minutes into a protected, billable, bureaucratic commodity. End the artificial scarcity, and American healthcare could become faster, cheaper, and vastly more humane almost overnight.

FDA Citizen Petition to Place all Non-Controlled Medications Over the Counter

 

CITIZEN PETITION

Universal Nonprescription Access for

FDA-Approved Human Drugs

Sole Exclusion: Federally Scheduled Controlled Substances

Including an evidence-based rebuttal to safety, access, economic, and implementation objections

Submitted under 21 C.F.R. Section 10.30

 

Policy request

Make every FDA-approved human drug available without a prescription or other FDA-created purchase gate unless it contains an active ingredient in federal Schedule I, II, III, IV, or V.

 

Important limitation

This petition does not claim that every noncontrolled drug is safe for unsupervised use, or that available evidence proves most prescription drugs are safer than most OTC drugs. It argues that legal availability is not a rank order of danger and that risk analysis must include the harms of undertreatment, delayed care, and cost barriers.

 

 

Dockets Management Staff (HFA-305)

Food and Drug Administration

5630 Fishers Lane, Room 1061

Rockville, Maryland 20852

Submitted: June 25, 2026

 

Citizen Petition

Date: June 25, 2026

The undersigned submits this petition under sections 503(b), 505, 505-1, and 701(a) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. Sections 353(b), 355, 355-1, and 371(a), and 21 C.F.R. Sections 10.30 and 310.200. Petitioner requests universal nonprescription access for approved human drugs that do not contain federally scheduled controlled substances; removal of every other FDA-created purchase condition; preservation of non-gating safety authorities; and a legislative recommendation for any part of the requested endpoint that current law does not authorize. [1]-[5][10]-[13]

Petitioner	Contact information
David Behar, MD	700 Hagys Ford Road, Penn Valley, PA 19072 dbehar322@gmail.com (610) 389-1716

 

Scope of request

All therapeutic fields, indications, strengths, dosage forms, routes, and populations are included. The single requested exclusion is a drug containing a federally scheduled controlled substance. Ordinary manufacturing, labeling, truthful-promotion, recall, and postmarket authority remain in force but may not be used as a retail purchase gate for included drugs.

 

Current-law notice

This filing requests a change in policy and, where necessary, federal law. It does not state that existing prescription drugs may currently be sold without a prescription, and it is not medical advice.

 

Contents

- A. Action Requested

- B. Statement of Grounds

- C. Environmental Impact

- D. Economic Impact

- E. Certification

- References and Citation Attachments

- Appendix A - Universal Inclusion Scope and Sole Exclusion

- Appendix B - Model Coverage Continuity and Neutrality Rule

- Appendix C - Non-Gating Consumer Information and Support Standard

- Appendix D - Model Federal Statutory Amendment

- Appendix E - Objections, Warnings, Unfavorable Evidence, and Rebuttals

- Appendix F - Access, Competition, Price, Utilization, and Profit Framework

A. Action Requested

Petitioner requests a universal nonprescription-access policy for every human drug approved under section 505 of the FD&C Act, with one categorical exclusion: a drug containing an active ingredient listed in Schedule I through V under the Controlled Substances Act. The requested endpoint is lawful retail purchase without a prescriber, prior diagnosis, laboratory test, questionnaire, pharmacist authorization, enrollment, certification, package limit, duration limit, or other FDA-created condition. [2]-[7][10]-[13]

1. Adopt universal nonprescription status. Every approved human drug that does not contain an Excluded Controlled Substance should be exempt from federal prescription-dispensing requirements and lawfully purchasable without a prescription.

2. Use one sole categorical exclusion. The only excluded class should be a drug containing an active ingredient listed in Schedule I, II, III, IV, or V under 21 U.S.C. Section 812 or 21 C.F.R. Part 1308, as amended. [10]-[12]

3. Remove all other FDA purchase gates. For included drugs, purchase should not depend on a prescription, practitioner order, pharmacist authorization, prior diagnosis, prior treatment, laboratory result, screening questionnaire, ACNU, REMS enrollment, age or sex verification, indication or strength limit, route or dosage-form limit, package size, quantity, duration, or refill rule.

4. Include every therapeutic field and product type. The rule should apply without categorical exception to psychiatric, neurologic, cardiovascular, endocrine, metabolic, oncology, immunologic, transplant, anti-infective, reproductive, respiratory, gastrointestinal, renal, urologic, dermatologic, ophthalmic, otic, emergency, anesthetic, and hospital-use drugs, and to every approved strength, dosage form, route, and population.

5. Initiate Commissioner-led class proceedings. FDA should create a master docket and coordinated class dockets, identify all approved noncontrolled products, and initiate section 310.200 proceedings rather than waiting exclusively for sponsor petitions. [3][6]

6. Amend 21 C.F.R. Section 310.200. FDA should adopt the proposed universal exemption text below to the fullest extent permitted by current law and identify the statutory amendment needed for the remainder. [2][3][5]

7. Remove conflicting FDA restrictions. FDA should revise approval conditions, guidance, labeling limitations, and REMS elements that operate as conditions of purchase for included drugs. Where current law prevents removal, FDA should transmit Appendix D. [4][7][13]

8. Use information rather than gatekeeping. FDA may require accurate labeling, warnings, directions, contraindications, packaging, manufacturing controls, safety communications, recalls, and adverse-event reporting, but those measures should not deny or delay purchase. [7]-[9][14]

9. Keep AI, testing, pharmacists, and clinicians optional. A consumer may voluntarily use an AI tool, laboratory test, pharmacist, clinician, telehealth service, or other support. Completion or approval by any service should never be a condition of purchase.

10. Apply the policy equally to brands and generics. Therapeutically equivalent products should transition on coordinated dates, with common consumer information where scientifically appropriate, so no sponsor receives an access monopoly.

11. Prevent a coverage cliff. FDA should publish a coverage-impact statement and formally refer Appendix B to HHS, CMS, the Departments of Labor and the Treasury, States, and Congress so reclassification does not terminate coverage solely because a product becomes nonprescription. [15][16][30]

12. Use postmarket surveillance without restoring a prescription gate. FDA should monitor adverse events, medication errors, overdose, interactions, delayed diagnosis, pregnancy outcomes, antimicrobial resistance, product quality, disparities, coverage loss, and shortages, and respond through non-gating authorities. [14][29]

13. Publish a comparative-risk and access report. FDA should compare the harms of use with the harms of nonuse, undertreatment, delayed treatment, current OTC substitution, and access friction. The report should not presume that OTC status means low risk or that prescription status means greater danger. [18]-[24]

14. Create a transparent price, utilization, safety, and supply dashboard. For each transitioned product or class, FDA and HHS should track cash price, out-of-pocket cost, coverage, manufacturer entry, utilization, treatment initiation, persistence, adverse events, poison-center signals, shortages, and disparities at 6, 12, 24, and 36 months. [22]-[30]

15. Transmit a legislative proposal. Within 180 days, FDA should send HHS and Congress the model language in Appendix D and a list of statutory provisions that prevent full implementation.

Proposed regulatory text

Current section 310.200(b) permits Commissioner-initiated prescription-exemption proceedings, but section 503(b) may not permit the full universal endpoint by regulation alone. FDA should adopt the following text to the fullest lawful extent and transmit Appendix D for the balance. [2][3][5]

(b) Universal prescription exemption. Except as provided in paragraph (c), every human drug approved under section 505 of the act is exempt from prescription-dispensing requirements and may be sold to a consumer without a prescription.

(c) Sole exclusion for federally controlled substances. Paragraph (b) does not apply to a drug containing an active ingredient listed in Schedule I, II, III, IV, or V under section 202 of the Controlled Substances Act or part 1308 of this title. The exclusion changes automatically when the federal schedule changes.

(d) No other purchase condition. For a drug covered by paragraph (b), FDA shall not require, as a condition of retail purchase, a prescription, practitioner order, pharmacist authorization, prior diagnosis, prior use, laboratory test, questionnaire, additional condition for nonprescription use, REMS enrollment or certification, age or sex verification, limitation by indication, strength, route, dosage form, package size, quantity, duration, refill, or any comparable condition.

(e) Information and postmarket authority preserved. Nothing in this section limits FDA authority to require accurate labeling, warnings, directions, contraindications, packaging, manufacturing controls, adverse-event reporting, postmarket studies, safety communications, recalls, or application changes, provided those measures do not operate as a condition of retail purchase for a drug covered by paragraph (b).

(f) Equal therapeutic scope. A drug shall not be excluded from paragraph (b) because of therapeutic field, toxicity, narrow therapeutic index, need for monitoring, pregnancy risk, route, dosage form, professional-use history, REMS status, antimicrobial status, psychiatric use, oncology use, or hospital-use history.

(g) Implementation. FDA shall publish a master list of included and excluded products, coordinate transition dates for therapeutically equivalent products, revise conflicting approval conditions and guidance, publish safety and economic monitoring results, and identify statutory barriers for referral to Congress.

B. Statement of Grounds

1. Current law provides the prescription standard, an exemption mechanism, and a limit on FDA's present authority.

Section 503(b) presently requires prescription dispensing when a drug is not safe for use except under practitioner supervision or when an approved application limits it to professional supervision. Section 310.200 preserves prescription status until FDA grants an exemption and allows the Commissioner to initiate the exemption proceeding. [2][3]

This petition asks FDA to use existing authority at the broadest lawful scale, build a public record, and state candidly where section 503(b) prevents the requested endpoint. It also asks FDA to recommend legislation rather than treating an asserted lack of authority as a reason not to evaluate universal access. [1][5]

2. The Controlled Substances Act supplies a distinct and administrable sole exclusion.

The Controlled Substances Act establishes Schedules I through V, current regulations identify scheduled substances, and federal law separately imposes prescription, medical-purpose, recordkeeping, and diversion controls. [10]-[12]

Under the requested bright-line rule, an approved drug enters or leaves the exclusion when its federal schedule changes. The petition acknowledges that scheduling does not capture every serious non-addiction risk and every misuse signal; it nevertheless supplies a defined federal boundary and a separate process for newly supported scheduling action.

3. Access barriers and undertreatment are safety outcomes, not merely conveniences.

A prescription requirement imposes time, travel, appointment, administrative, and financial costs before a consumer can obtain the product. FDA's ACNU regulatory impact analysis estimated a primary reduction in consumer access costs of $33.62 per purchase, with a range of $0 to $67.23, for a hypothetical prescription-to-nonprescription transition. FDA did not project national totals and emphasized uncertainty. [25]

National data show that access failures remain substantial. In 2024, 7.3% of adults failed to obtain needed medical care because of cost. In 2022, adults also reported delayed or forgone care because appointments were unavailable, they were too busy, offices were inaccessible when open, providers did not accept their insurance, or travel took too long. [22][23]

Mental-health undertreatment illustrates the stakes. In 2024, 29.5 million adults with any mental illness did not receive mental-health treatment; 6.1 million of those adults perceived an unmet need, and cost was among the most commonly reported reasons. These data do not prove that medication access alone resolves the treatment gap, but they establish that non-treatment and access friction must be included in the safety comparison. [24]

4. OTC and prescription status are legal access categories, not a rank ordering of danger.

FDA warns that excessive acetaminophen can cause severe liver damage, transplantation, and death; high-dose diphenhydramine can cause serious heart problems, seizures, coma, or death; and aspirin-containing antacid products can cause gastrointestinal bleeding that may require transfusion. These products are available without a prescription. [18]-[20]

Those examples do not prove that all or most prescription drugs are safer than all or most OTC drugs. No comprehensive dataset in this record supports that sweeping comparison. They do rebut the premise that OTC status is synonymous with low hazard or that prescription status necessarily identifies greater toxicity. The proper analysis is comparative and includes dose, use, population, untreated disease, substitution, and barriers to care.

Prescription status also does not eliminate harm. Shehab and colleagues estimated approximately four emergency-department visits for outpatient adverse drug events per 1,000 individuals annually in 2013-2014; 27.3% of estimated visits involved hospitalization. Commonly implicated classes included anticoagulants, diabetes agents, and opioid analgesics. [21]

5. Overdose and poisoning warnings are real, but they do not by themselves justify a universal permission gate.

Intentional overdose, accidental pediatric ingestion, duplicate ingredients, and dosing errors are representative unfavorable information. The petition does not ask FDA to hide or minimize them. It asks whether a prescription prerequisite is the least harmful and most effective response for every noncontrolled product.

Many overdose-prevention tools do not require advance permission: clear maximum-dose labeling, standardized ingredient names, child-resistant and unit-dose packaging, poison-control information, emergency instructions, public education, adverse-event signal detection, label changes, recalls, and scheduling referral when warranted. [14][18]-[21]

6. Misdiagnosis and delayed care must be compared with delay created by the current access model.

A consumer may self-treat the wrong condition, overlook a red flag, or postpone needed care. The opposite error also matters: a person may remain untreated because the appointment, cost, travel, scheduling, or administrative burden is too high. [22][23]

FDA should require clear limits-of-use and emergency-referral information and make professional support easy to obtain. The petition objects to turning those supports into prerequisites that recreate the barrier they are meant to solve.

7. Monitoring, interactions, pregnancy risks, and administration risks support information and services, but not necessarily denial of purchase.

Some included drugs require titration, sterile technique, laboratory interpretation, interaction review, therapeutic drug monitoring, pregnancy counseling, or rapid management of adverse effects. These concerns are serious and are not fully captured by the controlled-substance exclusion.

Petitioner asks FDA to distinguish a recommended clinical practice from a legal condition of ownership or purchase. Strong warnings, optional testing, private decision support, caregiver information, professional administration services, and postmarket action can remain. For any step current law requires as an element to assure safe use, Appendix D requests amendment. [13][14]

8. Psychiatric access requires balancing medication risk against the risks of untreated illness and interrupted care.

Warnings about activation, suicidality, sedation, withdrawal, relapse, and interaction must be prominent. At the same time, national data document a large mental-health treatment gap and frequent cost concerns. [24]

The petition therefore rejects a one-sided analysis in which the only counted harm is use of the medicine. FDA should also count non-initiation, interruption, relapse, crisis care, and adverse consequences of untreated disease, while preserving crisis information, optional counseling, and active surveillance.

9. Antimicrobial resistance is a major unfavorable externality and requires a national non-gating stewardship system.

CDC reports that bacterial antimicrobial-resistant hospital-onset infections caused by selected pathogens increased during the pandemic and that most remained above pre-pandemic rates in 2022. Unnecessary or incorrect antimicrobial use can harm both the user and the public. [29]

Petitioner nevertheless requests nonprescription purchase and proposes resistance surveillance, voluntary rapid testing, stewardship labeling, public reporting, restrictions on false or misleading promotion, and rapid public-health action. Residual resistance risk is acknowledged and should be measured rather than omitted.

10. Optional AI, laboratory testing, pharmacists, and clinicians can expand support without becoming exclusionary infrastructure.

Digital tools and professional services can identify interactions, organize symptoms, improve comprehension, provide monitoring, and refer emergencies. They can also produce false reassurance, false denial, privacy loss, algorithmic bias, data lock-in, and unequal access.

Appendix C permits prominent and convenient voluntary support but prohibits a purchase condition based on an account, identity check, score, answer, test, third-party payment, or data disclosure. Loss of a digital service must never interrupt product availability.

11. Coverage continuity is essential to prevent legal access from becoming financial inaccessibility.

Medicaid and Medicare rules do not treat all nonprescription products as covered prescription drugs. An OTC transition can therefore eliminate the prescriber gate while imposing a cash-price barrier. [15][16]

Evidence on cost sharing reinforces the concern. A systematic review and meta-analysis found increased odds of nonadherence in publicly insured populations exposed to prescription copayments. Appendix B requests permanent coverage of at least one therapeutic equivalent, reimbursement without a prescription-only visit, transition protection, and monitoring of abandonment. [30]

12. Competition can reduce prices, increase use, and create large commercial opportunities, but the outcome is not automatic.

FDA found that generic prices were lower relative to pre-entry brand prices as the number of competitors increased: the median AMP reduction was 39% with one generic producer, 54% with two, 79% with four, and more than 95% with six or more. FDA cautioned that these measures do not fully represent consumer prices and that very low prices can coincide with shortages. [26]

FDA separately estimated $18.6 billion in first-year net savings from 2023 generic approvals under its model. Such estimates support the value of entry but do not guarantee the retail price of any universal transition. [27]

Lower effective prices and lower access costs generally increase use, but sensitivity differs by drug and class. Einav, Finkelstein, and Polyakova found substantial heterogeneity in drug-specific and therapeutic-class demand elasticities. [28]

The commercial mechanism is straightforward: revenue equals price times quantity, and operating contribution can be represented as (price minus unit cost) times quantity minus fixed cost. A lower unit price can produce higher total revenue and potentially very large profit if volume expands enough and supply remains efficient. Petitioner expects this incentive to attract manufacturers and expand use, but does not claim that profit is guaranteed, that every class is elastic, or that profit is an FDA approval criterion. [25]-[28]

13. Market concentration, coverage changes, liability, and shortages can defeat the expected price-and-volume mechanism.

Prices may remain high if entry is limited, distribution is concentrated, payer coverage ends, liability or relabeling costs rise, or supply is fragile. Lower manufacturer prices may not reach consumers. Rapid utilization growth can also create shortages.

The requested implementation therefore coordinates brands and generics, prohibits an access monopoly, preserves coverage, publishes cash and out-of-pocket prices, tracks manufacturer entry and shortages, and asks competition authorities to review exclusionary conduct. [15][16][25]-[30]

14. A universal policy requires legislative candor and a transparent record.

Current section 503(b) expressly considers toxicity, harmful potential, method of use, and collateral measures. It may not permit FDA to exempt every noncontrolled drug without product-specific findings. Existing REMS provisions may also conflict with unrestricted purchase. [2][13]

The petition therefore asks FDA to act to the fullest lawful extent, open a public record, identify products and barriers, and transmit Appendix D. It does not represent that the universal endpoint is already authorized.

15. The petition includes warnings and unfavorable information rather than treating them as reasons to suppress the proposal.

Appendix E collects the principal medical, legal, economic, equity, antimicrobial, supply, and implementation objections and states residual risks. The petition's policy judgment is that non-gating information, voluntary services, coverage, and postmarket action are preferable to a legal purchase veto for noncontrolled drugs. FDA and Congress may disagree; the requested docket should make that disagreement evidence-based and transparent.

C. Environmental Impact

Petitioner claims categorical exclusion under 21 C.F.R. Section 25.30(h) for the requested initiation of rulemaking, guidance, public dockets, data collection, interagency referral, and legislative recommendation because those procedural actions do not themselves approve a particular drug, change a particular product's intended use, or authorize a particular increase in production. To petitioner's knowledge, no extraordinary circumstances exist for those procedural actions. [17]

If FDA treats a final universal exemption, a product-specific approval change, or another substantive implementation step as requiring an environmental assessment or a different categorical-exclusion analysis, petitioner requests that FDA sever or sequence that action and obtain the product-specific information required at that stage. This filing does not purport to supply product-specific environmental fate, manufacturing-volume, disposal, or ecological data. [17]

D. Economic Impact

Economic impact information will be submitted if requested under 21 C.F.R. Section 10.30(b). The central economic theory is that removing prescription acquisition costs and coordinating generic competition will reduce effective consumer cost, increase treatment initiation and continuation, expand quantity demanded, and create large revenue opportunities. FDA's own ACNU analysis recognizes meaningful access costs per purchase, and FDA's generic-competition work associates more competitors with lower manufacturer and pharmacy-acquisition price measures. [1][25]-[27]

The petition does not present price reductions, utilization increases, or manufacturer profit as certainties. Drug-specific demand is heterogeneous; retail and out-of-pocket prices depend on insurance, rebates, distribution, and market structure; and low prices can undermine supply resilience. [26][28]

For clarity, the proposed mechanism is: (1) remove a time and permission cost; (2) preserve coverage; (3) coordinate brand and generic transition; (4) lower cash and out-of-pocket price through entry and competition; (5) increase initiation, adherence, and persistence where demand responds; and (6) allow aggregate revenue and potentially profit to rise when added volume more than offsets lower unit margin and fixed costs. Appendix F states the assumptions, countervailing forces, and required measures.

Economic evaluation should report results separately for Medicare, Medicaid, employer coverage, Marketplace coverage, uninsured consumers, rural communities, people with disabilities, limited-English-proficiency populations, and consumers who do not use digital tools. It should include adverse events, emergency care, antimicrobial resistance, product liability, relabeling costs, manufacturing investment, shortage risk, and FDA, HHS, and DEA administrative costs. [15][16][22]-[30]

The agency should not count a manufacturer's expected profit as a public-health benefit by itself. Profit is relevant as an incentive for entry, production, distribution, lower prices, innovation, and promotion, and it can be large when market expansion is substantial. The public-interest measures are affordable access, appropriate use, health outcomes, equity, safety, and reliable supply.

E. Certification

The undersigned certifies, that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner which are unfavorable to the petition.

David Behar, MD

700 Hagys Ford Road

Penn Valley, PA 19072

Telephone: (610) 389-1716

Email: dbehar322@gmail.com

Date: June 25, 2026

 

References and Citation Attachments

Each numbered citation below corresponds to a PDF in the references folder and in the compiled Reference Source Volume. The filing includes complete PDFs for every cited peer-reviewed journal article. Government webpages that did not provide a stable agency PDF are included as clearly labeled filing-generated webpage captures; the source URL and content date appear on each capture.

1. 21 C.F.R. Section 10.30, "Citizen petition". Attachment: Ref_01_21_CFR_10_30_Citizen_Petition.pdf. Petition format and certification.

2. 21 U.S.C. Section 353(b), prescription dispensing and exemption standards. Attachment: Ref_02_21_USC_353_Prescription_Standard.pdf. Current prescription-supervision standard.

3. 21 C.F.R. Section 310.200, prescription-exemption procedure. Attachment: Ref_03_21_CFR_310_200_Prescription_Exemption.pdf. Commissioner- or petitioner-initiated exemption procedure.

4. 21 U.S.C. Section 355, new-drug approval provisions. Attachment: Ref_04_21_USC_355_New_Drugs.pdf. Approval authority.

5. 21 U.S.C. Section 371, regulations and hearings. Attachment: Ref_05_21_USC_371_Regulations_and_Hearings.pdf. General rulemaking authority.

6. FDA, Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments, 91 Fed. Reg. 20170. Attachment: Ref_06_FDA_Increasing_Access_Public_Meeting_2026.pdf. Current access initiative and public docket.

7. Current OTC Drug Facts and ACNU regulations, 21 C.F.R. Sections 201.66, 201.67, 201.130, and 314.56. Attachment: Ref_07_Current_OTC_and_ACNU_Regulations.pdf. Nonprescription labeling and additional-condition framework.

8. FDA Guidance: Label Comprehension Studies for Nonprescription Drug Products. Attachment: Ref_08_FDA_Label_Comprehension_Guidance.pdf. Consumer understanding studies.

9. FDA Guidance: Self-Selection Studies for Nonprescription Drug Products. Attachment: Ref_09_FDA_Self_Selection_Studies_Guidance.pdf. Consumer self-selection studies.

10. 21 U.S.C. Section 812, establishment of controlled-substance schedules. Attachment: Ref_10_21_USC_812_Controlled_Substance_Schedules.pdf. Schedules I-V.

11. 21 U.S.C. Section 829, prescriptions for controlled substances. Attachment: Ref_11_21_USC_829_Controlled_Substance_Prescriptions.pdf. Prescription rules for scheduled drugs.

12. 21 C.F.R. Part 1308, federal controlled-substance schedules. Attachment: Ref_12_21_CFR_Part_1308_Controlled_Substance_Schedules.pdf. Current regulatory schedules.

13. 21 U.S.C. Section 355-1, risk evaluation and mitigation strategies. Attachment: Ref_13_21_USC_355_1_REMS.pdf. REMS and elements to assure safe use.

14. 21 C.F.R. Section 314.80, postmarketing adverse-drug-experience reporting. Attachment: Ref_14_21_CFR_314_80_Postmarketing_Reporting.pdf. Postmarket reporting authority.

15. 42 U.S.C. Section 1396r-8, Medicaid outpatient-drug provisions. Attachment: Ref_15_42_USC_1396r_8_Medicaid_OTC.pdf. Medicaid treatment of nonprescription drugs.

16. CMS, Over-the-Counter Drug Reference File Frequently Asked Questions. Attachment: Ref_16_CMS_OTC_Reference_File_FAQ.pdf. Coverage and rebate administration.

17. 21 C.F.R. Part 25 environmental assessment and categorical-exclusion provisions. Attachment: Ref_17_Current_Environmental_Impact_Regulations.pdf. Environmental statement.

18. FDA, Don't Overuse Acetaminophen. Attachment: Ref_18_FDA_Acetaminophen_Consumer_Update_Webpage_Capture.pdf. OTC overdose, liver failure, transplant, and death warning.

19. FDA, High-dose diphenhydramine warning. Attachment: Ref_19_FDA_Diphenhydramine_High_Dose_Warning_Webpage_Capture.pdf. OTC heart problems, seizures, coma, and death warning.

20. FDA, Aspirin-containing antacid bleeding warning. Attachment: Ref_20_FDA_Aspirin_Antacid_Bleeding_Warning_Webpage_Capture.pdf. OTC gastrointestinal bleeding warning.

21. Shehab et al., U.S. Emergency Department Visits for Outpatient Adverse Drug Events, JAMA 316:2115-2125 (2016). Attachment: Ref_21_Shehab_JAMA_Outpatient_Adverse_Drug_Events.pdf. Burden and drug classes involved in outpatient adverse drug events.

22. NCHS, Early Release of Selected Estimates Based on the 2024 National Health Interview Survey. Attachment: Ref_22_CDC_2024_NHIS_Early_Release_Access_to_Care.pdf. Cost-related unmet medical care.

23. NCHS, Sociodemographic Differences in Nonfinancial Access Barriers to Health Care Among Adults: United States, 2022. Attachment: Ref_23_CDC_Nonfinancial_Access_Barriers_2022.pdf. Appointment, time, travel, insurance acceptance, and other access barriers.

24. SAMHSA, 2024 NSDUH mental-health treatment-gap extract. Attachment: Ref_24_SAMHSA_2024_NSDUH_Mental_Health_Treatment_Gap_Official_Extract.pdf. Mental-health undertreatment and perceived cost barrier.

25. FDA, Final Regulatory Impact Analysis for Nonprescription Drug Product With an ACNU. Attachment: Ref_25_FDA_ACNU_Final_Regulatory_Impact_Analysis.pdf. Estimated consumer access-cost reduction and economic uncertainties.

26. FDA, Generic Competition and Drug Prices: New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices. Attachment: Ref_26_FDA_Generic_Competition_and_Drug_Prices.pdf. Generic entry and lower manufacturer/wholesale price measures, with limitations.

27. FDA, Estimated Savings From Generic Drug Approvals in 2023. Attachment: Ref_27_FDA_Generic_Approvals_Savings_2023.pdf. Estimated savings associated with generic approvals.

28. Einav, Finkelstein, and Polyakova, Drug-Specific Price Elasticities and Cost Sharing in Medicare Part D, AEJ: Economic Policy 10(3):122-153 (2018). Attachment: Ref_28_Einav_Finkelstein_Polyakova_Drug_Price_Elasticities.pdf. Demand responds to out-of-pocket price, with substantial heterogeneity.

29. CDC, Antimicrobial Resistance Threats in the United States, 2021-2022. Attachment: Ref_29_CDC_Antimicrobial_Resistance_Threats_2021_2022.pdf. Antimicrobial-resistance burden and stewardship warning.

30. Sinnott et al., Effect of Copayments on Medication Adherence, PLOS ONE 8(5):e64914 (2013). Attachment: Ref_30_Sinnott_PLOS_Copayments_and_Medication_Adherence.pdf. Copayments and nonadherence in publicly insured populations.

 

APPENDIX A

Universal Inclusion Scope and Sole Exclusion

This Appendix is incorporated into the petition. Every human drug approved under section 505 is requested to be available for nonprescription purchase unless it contains an active ingredient listed in Schedule I through V under the Controlled Substances Act. No other negative list, risk tier, continuation-only pathway, test, diagnosis, package limit, strength limit, indication limit, or route limit is requested. [2]-[4][10]-[12]

1. Operative definitions

- Included drug: any human drug with an effective section 505 approval that does not contain an Excluded Controlled Substance.

- Excluded Controlled Substance: an active ingredient listed in federal Schedule I, II, III, IV, or V under 21 U.S.C. Section 812 or 21 C.F.R. Part 1308, as amended.

- Purchase gate: any prescription, practitioner order, pharmacist approval, test, questionnaire, prior diagnosis, prior treatment, enrollment, certification, identity or age verification, indication or strength restriction, route restriction, package or quantity limit, duration limit, refill rule, ACNU, REMS condition, or comparable prerequisite imposed under FDA authority as a condition of retail purchase.

- Non-gating safety measure: labeling, warnings, directions, contraindications, packaging, manufacturing controls, adverse-event reporting, safety communications, recalls, or postmarket studies that do not prevent or delay purchase.

2. Universal therapeutic inclusion

Therapeutic field	Representative included scope	Requested access
Primary care and internal medicine	Pain, fever, allergy, respiratory, gastrointestinal, renal, hepatic, hematologic, infectious, and multisystem drugs	Unrestricted nonprescription purchase unless federally scheduled
Psychiatry and neurology	Antidepressants, antipsychotics, mood stabilizers, noncontrolled ADHD drugs, anticonvulsants, migraine, dementia, Parkinson disease, and sleep drugs	Unrestricted nonprescription purchase unless federally scheduled
Cardiovascular and coagulation	Antihypertensives, antiarrhythmics, anticoagulants, antiplatelet drugs, lipid drugs, heart-failure drugs, and pulmonary-vascular drugs	Unrestricted nonprescription purchase unless federally scheduled
Endocrine and metabolic	Insulin and other diabetes drugs, thyroid drugs, adrenal drugs, osteoporosis drugs, vitamins, minerals, and metabolic-disease therapies	Unrestricted nonprescription purchase unless federally scheduled
Oncology, immunology, and transplant	Cytotoxic drugs, targeted therapies, immunotherapies, immunosuppressants, and transplant drugs approved under section 505	Unrestricted nonprescription purchase unless federally scheduled
Anti-infective	Systemic and local antibacterial, antiviral, antifungal, antiparasitic, and antimycobacterial drugs	Unrestricted nonprescription purchase unless federally scheduled
Reproductive and sexual health	Contraception, fertility, pregnancy-related, menopause, erectile-dysfunction, gynecologic, and urologic drugs	Unrestricted nonprescription purchase unless federally scheduled
Emergency, anesthetic, and hospital-use	Emergency drugs, anesthetics, vasopressors, inotropes, neuromuscular blockers, contrast agents, and procedure-associated drugs	Unrestricted nonprescription purchase unless federally scheduled
Dermatologic, ophthalmic, otic, and local therapy	Topical, ocular, otic, nasal, inhaled, vaginal, rectal, transdermal, and implantable drugs	Unrestricted nonprescription purchase unless federally scheduled

 

3. All strengths, dosage forms, routes, and populations

- All approved strengths and concentrations are included.

- All approved dosage forms and routes are included, including oral, topical, transdermal, inhaled, nasal, ophthalmic, otic, vaginal, rectal, injectable, infused, implanted, and device-combination presentations.

- All approved indications and populations are included. Labeling may describe approved use, contraindications, and warnings but should not be a purchase condition.

- Initiation, titration, continuation, refill, rescue, and maintenance use receive the same nonprescription status.

- Brand and therapeutically equivalent generic products transition together.

4. Sole excluded category

Controlled category	Products remaining outside the requested policy
Controlled opioids	Schedule II-V opioid analgesics and other scheduled opioid products
Controlled stimulants	Amphetamine, methylphenidate, and other scheduled stimulants
Benzodiazepines and controlled sedative-hypnotics	Scheduled anxiolytic, sedative, hypnotic, and related products
Barbiturates and other controlled depressants	Scheduled barbiturate and depressant products
Controlled anabolic steroids and testosterone	Products listed in federal controlled-substance schedules
Other Schedule I-V substances	Any current or future active ingredient in 21 U.S.C. Section 812 or 21 C.F.R. Part 1308

 

A product removed from all federal schedules would enter the included category without a separate FDA negative-list proceeding. A newly scheduled product would enter the exclusion on the effective date of scheduling. [10]-[12]

 

APPENDIX B

Model Rx-to-OTC Coverage Continuity and Neutrality Rule

1. Purpose. Prevent nonprescription reclassification from causing loss of affordable access, treatment interruption, or a visit required solely for reimbursement.

2. Covered reclassified drug. Any drug or therapeutic equivalent that becomes nonprescription under the requested policy.

3. Coverage continuity. A plan that covered a prescription version immediately before reclassification may not terminate coverage solely because the product is nonprescription. The plan shall cover at least one FDA-approved therapeutic equivalent at cost sharing no less favorable than the pre-switch preferred option, subject only to clinically neutral formulary management.

4. Universal therapeutic neutrality. The rule applies equally to psychiatric, oncology, anti-infective, reproductive, metabolic, emergency, and all other included therapeutic areas.

5. No reimbursement-only prescription or visit. A plan may not require an office visit or prescription whose sole purpose is reimbursement when federal law permits nonprescription purchase. Plans should accept a pharmacy claim, NDC, itemized receipt, standing order, or another reasonable proof of purchase.

6. Medicaid transition. CMS should issue model State-plan and rebate guidance, identify lawful pathways under 42 U.S.C. Section 1396r-8, and recommend statutory change where a prescription condition would cause a coverage cliff. [15]

7. Medicare transition. HHS should propose legislation or other lawful authority to maintain coverage for a product that moves from covered prescription status to nonprescription status. [16]

8. Notice and transition. Plans shall provide clear advance notice, at least a 90-day transition supply or equivalent access, an exception process, and continuity during a timely appeal.

9. Permissible neutral management. A payer may use preferred products, generic substitution, fraud controls, and ordinary claims administration that do not penalize a product solely because it is nonprescription.

10. Data and audit. HHS and States should report coverage retention, abandonment, out-of-pocket spending, utilization, emergency care, treatment continuity, and disparate effects.

11. Duration. Coverage continuity should be permanent for at least one clinically appropriate equivalent, not merely a brief transition benefit.

Jurisdiction note

FDA can document and refer coverage consequences but cannot, through drug-approval authority alone, bind every public or private payer. This model is directed to HHS, CMS, the Departments of Labor and the Treasury, States, and Congress. [15][16]

 

 

APPENDIX C

Non-Gating Consumer Information and Support Standard

This Appendix preserves consumer information and voluntary support while implementing the no-restriction rule. None of the following may be required before purchase, used to deny purchase, or conditioned on payment to or data sharing with a third-party service. [7]-[9]

1. Drug Facts and approved information. Clear approved uses, directions, contraindications, warnings, interactions, pregnancy information, overdose information, storage, and emergency instructions in accessible formats.

2. Optional pharmacist or clinician consultation. Retailers may make consultation or referral available, but the consumer may decline without losing access.

3. Optional AI and digital tools. A consumer may use an interaction checker, symptom organizer, educational chatbot, dose reminder, or other tool. No score, answer, identity check, account, or algorithmic approval may be required.

4. Optional laboratory testing. A consumer may obtain baseline or monitoring tests voluntarily. A result, proof of testing, standing order, or laboratory account may not be required.

5. No mandatory health-data collection. Purchase should not require disclosure of diagnosis, medication history, pregnancy status, laboratory data, identity, insurance, or other health information beyond separate law governing an ordinary retail transaction.

6. Emergency and poison information. Products should prominently identify emergency symptoms, poison-control resources, overdose response, and the limits of self-treatment.

7. Multiple formats. Information should be available on the package and optionally by paper insert, telephone, accessible website, audio, video, and translated materials. Loss of a digital service must not interrupt access.

8. Postmarket learning. Sponsors and FDA should analyze adverse events, medication errors, overdose, interactions, delayed diagnosis, product misuse, resistance, and disparities and update information promptly. [14][29]

9. No conversion into a gate. FDA, a sponsor, retailer, payer, platform, laboratory, pharmacist, or clinician should not convert an informational or support service into a prerequisite for retail purchase.

 

APPENDIX D

Model Federal Statutory Amendment

The following model is requested if FDA concludes that current law does not permit full implementation. It is proposed legislative language, not a statement of current law.

SECTION 1. UNIVERSAL NONPRESCRIPTION STATUS FOR NONCONTROLLED APPROVED HUMAN DRUGS.

(a) Amendment to section 503(b). Section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act is amended to provide that, except for a drug containing a controlled substance listed in Schedule I, II, III, IV, or V under section 202 of the Controlled Substances Act, a human drug with an effective approval under section 505 shall not be limited to dispensing upon a prescription.

(b) Sole exclusion. The Secretary may not establish an additional categorical exclusion from nonprescription status for a drug covered by subsection (a). A change in federal scheduling shall automatically change the drug's status under subsection (a).

(c) No condition of purchase under the FD&C Act. For a drug covered by subsection (a), the Secretary may not require under the FD&C Act, as a condition of retail purchase, a prescription, practitioner order, pharmacist authorization, prior diagnosis, prior use, laboratory test, questionnaire, ACNU, REMS enrollment or certification, age or sex verification, limitation by indication, strength, route, dosage form, package size, quantity, duration, refill, or a comparable condition.

(d) Safety authorities preserved. The Secretary may require accurate labeling, warnings, directions, contraindications, packaging, manufacturing controls, adverse-event reporting, postmarket studies, safety communications, recalls, and application changes, provided those measures do not operate as a condition of retail purchase.

(e) Conforming amendment to section 505-1. Section 505-1 is amended so that an element to assure safe use may not operate as a condition of retail purchase for a drug covered by subsection (a). Medication Guides, communication plans, packaging, postmarket studies, and non-gating risk information may continue.

(f) Coverage recommendation. The Secretary shall submit proposed conforming amendments to Medicare, Medicaid, and other federal health programs to prevent loss of coverage solely because a drug becomes nonprescription.

(g) Competition and coordinated transition. The Secretary shall coordinate transition dates for therapeutically equivalent products, avoid conferring exclusive nonprescription access on one sponsor, and report manufacturer entry, prices, coverage, utilization, safety, and shortages.

(h) Effective date and transition. The amendments take effect 24 months after enactment. FDA shall publish the list of excluded scheduled products and coordinate relabeling and transition dates for included products.

(i) Rule of construction. Nothing in this section changes the Controlled Substances Act or authorizes distribution or dispensing of a federally scheduled substance contrary to that Act. Separate statutes administered by another federal agency remain in effect unless Congress expressly amends them.

 

APPENDIX E

Objections, Warnings, Unfavorable Evidence, and Rebuttals

This Appendix is incorporated into the certification. It states material arguments against the requested policy, the petitioner's response, and residual safeguards. A rebuttal does not erase the stated risk; it explains why petitioner believes a purchase gate is not the preferred response.

Objection or warning	Petitioner's rebuttal	Residual safeguard / limitation
OTC conversion will cause overdose and poisoning.	The warning is serious. The relevant comparison, however, is not risk versus zero risk. Widely available OTC products already can cause fatal liver injury, seizures, coma, and major bleeding. Availability status is not an ordinal toxicity ranking. For a switch candidate, FDA should compare incremental access risk with harms of untreated disease, delayed treatment, substitution, and current access friction. [18]-[21]	Prominent overdose instructions, child-resistant packaging, unit-dose options, poison-control information, rapid label updates, surveillance, and recall authority; no pre-purchase gate.
The petition improperly claims all OTC drugs are more dangerous than most prescription drugs.	The petition makes no universal numerical claim. The evidence supports a narrower and important point: some common OTC drugs carry severe or fatal risks, and many noncontrolled prescription drugs may have lower absolute risk in particular uses. Therefore, the OTC/Rx boundary cannot be defended as a simple rank ordering of danger. Comparative product-level data remain necessary. [18]-[21]	FDA should publish a transparent comparative-risk framework and state uncertainty rather than presume either category is uniformly safer.
Consumers cannot diagnose themselves and may delay needed care.	Misdiagnosis and delay occur under every access model, including when people cannot obtain appointments. In 2022, adults reported appointment, time, travel, and insurance-acceptance barriers; in 2024, 7.3% of adults failed to obtain needed medical care because of cost. Removing a prescription gate can reduce one source of delay, while labels can identify red flags and the limits of self-treatment. [22][23]	Clear stop-use/referral warnings, optional triage tools and professional consultation, and postmarket monitoring of delayed diagnosis.
Physician supervision prevents adverse drug events.	Professional care can add value, but prescription status does not eliminate adverse events. A national study estimated about four emergency-department visits for outpatient adverse drug events per 1,000 individuals annually, and more than one quarter resulted in hospitalization. The question is whether mandatory permission adds enough net benefit to justify the access cost for each product and use. [21]	Voluntary clinical care, medication review, electronic interaction tools, pharmacovigilance, and targeted safety communications.
Drug interactions and polypharmacy make unrestricted access unsafe.	Interactions are real for both OTC and prescription products. Mandatory prescribing is an imperfect proxy for complete medication reconciliation, especially across fragmented systems. Universal access should be paired with standardized interaction warnings and optional private interaction checking, not a legal purchase veto.	Prominent contraindications, standardized ingredient names, voluntary pharmacist/clinician review, and nonmandatory digital checks.
Narrow-therapeutic-index drugs require laboratory or therapeutic monitoring.	Monitoring may improve outcomes, but the petition distinguishes a recommended clinical practice from a legal purchase condition. A consumer should be able to obtain a drug without proving a test, while receiving unmistakable information about why monitoring is recommended and what symptoms require urgent care.	Optional low-cost testing, standing access to results, strong labeling, and class-specific surveillance; FDA may change warnings or indications without restoring a purchase gate.
Pregnancy, fetal toxicity, and reproductive risks require screening.	These risks are substantial and must be disclosed. Mandatory pregnancy testing or sex verification can also create delay, privacy burdens, and inequitable denial. The petition requests information, confidential voluntary testing, and urgent referral pathways rather than compulsory proof before purchase.	Boxed and Drug Facts warnings, optional tests, emergency contact information, pregnancy registries, and rapid safety action.
Psychiatric medicines could increase self-harm, activation, withdrawal, or inappropriate use.	Psychiatric illness is also widely undertreated. In 2024, 29.5 million adults with any mental illness did not receive mental-health treatment; among those reporting unmet need, cost was a common reason. The access benefit does not erase suicide, activation, or withdrawal risks, but those risks should be weighed against non-treatment and interrupted treatment rather than treated as one-sided. [24]	Crisis warnings, small initial packages offered voluntarily, refill continuity, optional counseling, adverse-event surveillance, and immediate emergency guidance.
Antimicrobials will be overused and accelerate resistance.	Antimicrobial resistance is a major public-health externality, and the petition does not minimize it. The petition nonetheless rejects a purchase gate and instead asks for strong stewardship information, diagnostic access, resistance surveillance, dispensing data analysis, and rapid label changes. CDC found resistant hospital-onset infections remained elevated in 2022. [29]	National resistance dashboard, voluntary rapid testing, stewardship messages, limits on promotion, and public-health response; residual externality acknowledged.
REMS drugs and professional-use drugs cannot be made nonprescription safely.	Some current REMS elements and administration methods are designed around professional control. The petition asks FDA to separate purchase from administration and to retain non-gating information, training, packaging, postmarket studies, and facility standards imposed under other lawful authorities. Current section 505-1 may require legislation for full implementation. [13]	Legislative amendment, product-quality controls, optional trained administration, and immediate enforcement for unsafe promotion or manufacturing.
Children, older adults, and cognitively impaired consumers are especially vulnerable.	Vulnerability argues for accessible information, caregiver tools, child-resistant packaging, and coverage - not automatically for a permission system that can itself deny or delay care. The net effect may differ by population and must be measured.	Age-appropriate warnings, caregiver materials, accessible formats, poison prevention, and stratified safety reporting.
Noncontrolled drugs can still be misused, diverted, or addictive.	Controlled-substance scheduling is not a perfect predictor of misuse potential. That is unfavorable to the petition and is expressly acknowledged. The requested bright line uses the existing federal scheduling process; FDA and DEA may refer newly supported scheduling actions through that system. [10]-[12]	Misuse surveillance, scheduling referral when statutory criteria are met, anti-counterfeit controls, and truthful risk communication.
Removing gates will increase counterfeit and unsafe online purchasing.	A legal domestic channel can reduce incentives to use illicit sellers, but it cannot eliminate counterfeits. The policy should preserve FDA registration, manufacturing, labeling, track-and-trace, import, and enforcement authority.	Verified supply chains, public authentication tools, enforcement, recalls, and warnings about unlawful sellers.
Insurance will stop covering products after an OTC switch.	This is a major risk. A legal access reform that creates a cash-price barrier could worsen inequity and reduce adherence. The petition therefore requests permanent coverage continuity for at least one therapeutic equivalent and no reimbursement-only prescription visit. [15][16][30]	Appendix B coverage rule, claims pathways without a prescription, transition protection, and reporting of abandonment and out-of-pocket spending.
Market forces may not lower prices.	Competition often lowers manufacturer and wholesale price measures, but not automatically. FDA found larger generic price reductions with more competitors, while expressly warning that those measures do not fully capture consumer prices and that very low prices may coincide with shortages. [26]	Coordinated multi-manufacturer transition, generic substitution, transparent cash prices, anti-competitive enforcement referrals, and shortage monitoring.
Lower prices may not materially increase treatment use.	Demand for medicines is generally price responsive, but elasticities differ substantially by drug and class. Copayment evidence also links cost sharing with lower adherence. The petition therefore predicts an average access effect, not a uniform response for every drug or person. [28][30]	Measure utilization, initiation, persistence, adherence, and unmet need by product and population; revise implementation when expected access gains fail to occur.
The petition promises manufacturers huge profits.	It does not. Lower unit prices can coexist with higher total revenue and potentially large profits when the increase in volume is sufficient, but profit depends on unit margin, fixed cost, competition, payer behavior, liability, and supply. FDA is not asked to guarantee profits, and profit is not the legal approval standard. [25]-[28]	Publish price, entry, volume, shortage, and where lawful aggregate revenue indicators; prevent exclusive switch advantages and coordinate generics.
A universal policy is overbroad and not supported by product-specific evidence.	This is the strongest legal and evidentiary objection. Current section 503(b) is product- and supervision-focused. Petitioner asks FDA to use existing authority to the fullest extent, create a transparent record, and send Congress the model amendment needed for the universal endpoint. [2][3][5]	Phased administrative work, explicit statutory referral, public docket, and no claim that current law already authorizes every requested step.

 

 

APPENDIX F

Access, Competition, Price, Utilization, and Profit Framework

This Appendix translates the petition's economic claims into testable propositions. It does not promise a particular retail price, utilization response, revenue level, or profit outcome.

1. Proposed causal chain

Policy step	Expected mechanism	Evidence / limitation
Remove the permission and appointment gate	Reduce time, travel, scheduling, copay, and administrative costs before acquisition	FDA ACNU analysis estimates a primary $33.62 reduction in access cost per purchase in its modeled setting. [25]
Preserve insurance coverage	Prevent legal access from becoming a cash-price barrier	Medicaid and Medicare rules require coordinated coverage action; cost sharing can reduce adherence. [15][16][30]
Coordinate multiple brand/generic entrants	Increase price competition and avoid a single-sponsor access monopoly	FDA observed greater generic competition associated with lower manufacturer/wholesale price measures. [26][27]
Lower effective patient price	Increase initiation, refill, adherence, and persistence where demand responds	Drug and class elasticities are heterogeneous but generally negative; copayments are associated with nonadherence. [28][30]
Increase quantity and continuity	Reduce undertreatment and treatment interruption for responsive conditions	National surveys document cost and nonfinancial access barriers and mental-health treatment gaps. [22]-[24]
Expand market volume	Allow total revenue and potentially profit to rise despite lower unit price	Outcome depends on volume response, unit cost, fixed cost, competition, coverage, liability, and supply; not guaranteed. [25]-[28]

 

2. Basic commercial arithmetic

Revenue = P x Q. Operating contribution can be represented as (P - c) x Q - F, where P is net unit price, Q is quantity, c is variable unit cost, and F is fixed cost. A lower P can produce greater revenue and profit when Q rises sufficiently and unit cost and fixed costs remain controlled. Conversely, intense competition, weak demand response, coverage loss, liability, or shortages can reduce or eliminate profit.

3. Why the petition expects lower prices and higher use

Removing acquisition friction lowers the full price of obtaining treatment even if the package price is unchanged. Coordinated generic entry can lower manufacturer and acquisition price measures. Lower out-of-pocket cost tends to increase utilization or adherence, although the size of the response varies. [25][26][28][30]

4. Why large profits are possible but not assured

A transition can open a much larger self-pay and retail market, eliminate some prescriber-acquisition friction, and expand volume. Efficient producers may earn very large aggregate profits if the market expansion outweighs lower margins. That commercial opportunity can motivate investment and distribution. It is a hypothesis to be tested, not a promised result, a reason to tolerate monopoly, or a substitute for FDA's public-health standards.

5. Implementation levers

- Coordinate transition dates for therapeutically equivalent brands and generics.

- Do not confer an exclusive OTC or nonprescription position on one sponsor when equivalent products can transition.

- Preserve coverage for at least one equivalent and permit claims without a prescription-only visit.

- Publish cash prices and typical out-of-pocket prices in comparable units.

- Monitor manufacturer entry, exit, production capacity, quality events, and shortages.

- Refer exclusionary conduct, collusion, or anticompetitive distribution practices to the appropriate competition authority.

- Prohibit false or misleading claims that nonprescription status means the product is harmless.

6. Required dashboard

Domain	Measures
Access	Time to acquisition; travel; failed attempts; availability by geography; optional-service uptake
Affordability	List, cash, acquisition, and out-of-pocket price; coverage retention; claim rejection; abandonment
Use	New starts; total units; persistence; refill gaps; discontinuation; indication mix where lawful
Undertreatment	Condition-specific untreated or undertreated rates; self-reported unmet need; delay to therapy
Safety	Adverse events; ED visits; hospitalization; fatality; medication error; intentional and accidental overdose
Public-health externalities	Antimicrobial resistance; diversion; counterfeit events; product disposal and environmental signals
Competition and supply	Number of manufacturers; concentration; entry/exit; quality failures; shortages; back orders
Commercial outcomes	Where lawful, aggregate sales volume, revenue indicators, and investment; no confidential-data mandate beyond authority
Equity	All metrics stratified by insurance, income, age, disability, race/ethnicity where lawful, rurality, language, and digital access

 

7. Review triggers

- A statistically credible increase in severe adverse outcomes should trigger immediate investigation, labeling, packaging, recall, manufacturing, promotion, or scheduling action, not an automatic unexamined return to a prescription gate.

- A coverage decline or sharp out-of-pocket increase should trigger payer and legislative intervention under Appendix B.

- A shortage or concentration signal should trigger supply and competition review.

- Failure to reduce undertreatment should trigger examination of price, coverage, information, and distribution barriers rather than an assumption that legal availability alone was sufficient.

- All public reports should state uncertainty, comparison groups, confounding, and whether effects differ by product or population.